Search

Your search keyword '"Leleu, A."' showing total 109 results

Search Constraints

Start Over You searched for: Author "Leleu, A." Remove constraint Author: "Leleu, A." Journal leukemia Remove constraint Journal: leukemia
109 results on '"Leleu, A."'

Search Results

1. Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study: MULTIPLE MYELOMA, GAMMOPATHIES

2. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

4. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

5. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

6. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

7. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

9. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

12. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

13. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

14. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

15. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

16. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

18. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

21. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

22. Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods

25. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

26. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

31. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

32. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

33. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

35. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

37. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

38. Erratum: Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

39. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

40. Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma

41. Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

42. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma

43. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

45. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

46. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

47. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma

48. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

49. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

50. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Catalog

Books, media, physical & digital resources